StockNews.AI

LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders

StockNews.AI • 2 days

LSBCFLSBWF
High Materiality9/10

Information

BEIJING, Jan. 20, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "C...

Original source

AI Summary

LakeShore Biopharma plans an extraordinary general meeting for shareholders on February 12, 2026, to vote on a merger with Oceanpine Skyline Inc. If approved, LSB will become privately held, ceasing its public listing, which may significantly impact shareholder liquidity.

Sentiment Rationale

The merger will lead to loss of public trading, negatively impacting stock price and liquidity. Historical cases show that similar mergers often lead to initial sell-offs from concerned investors.

Trading Thesis

Investors should consider potential volatility and exit opportunities before merger execution.

Market-Moving

  • Merger approval could lead to significant sell-off due to loss of public trading.
  • Decreased liquidity post-merger may affect LSB's valuation and investor sentiment.
  • Shareholder voting outcomes can create immediate volatility in LSB's shares.
  • Potential competing offers may arise before the shareholder meeting.

Key Facts

  • LSB called an extraordinary general meeting on February 12, 2026.
  • Shareholders will vote on a proposed merger with Oceanpine Skyline Inc.
  • Successful merger will make LSB a privately held entity.
  • Shares will no longer be listed on public marketplaces post-merger.
  • Record shareholders as of January 16, 2026, can vote at the meeting.

Companies Mentioned

  • Oceanpine Skyline Inc. (N/A): Parent company for the merger, pivotal in changing LSB's structure.

M&A

This news falls under 'M&A' as it involves a proposed merger affecting shareholder structure and company operation. The shift to private ownership could alter LSB's future funding and operational strategies significantly.

LakeShore Biopharma Announces Extraordinary General Meeting of Shareholders

LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSB), a global leader in biopharmaceutical innovations, has called for an extraordinary general meeting (EGM) of its shareholders. Scheduled for February 12, 2026, at 11 a.m. local time in Beijing, this pivotal meeting aims to address several significant proposals, including a crucial merger agreement.

Details of the Extraordinary General Meeting

The EGM will take place at the following location:

Unit 1301, Tower 1,
China Central Place,
No. 81 Jianguo Road,
Chaoyang District, Beijing,
People's Republic of China

Shareholders will consider and vote on the proposed Agreement and Plan of Merger (the "Merger Agreement") with Oceanpine Skyline Inc. and its subsidiary, Oceanpine Merger Sub Inc., which was originally announced on November 4, 2025.

Implications of the Merger

According to the terms of the Merger Agreement, the merger will lead to the complete acquisition of LakeShore Biopharma by Oceanpine Merger Sub Inc. Upon completion, the Company will operate as a privately held entity. The ordinary shares, with a par value of US$0.0002, and associated warrants will no longer be listed on public marketplace systems, including the OTC Pink tier of the OTC Markets. Additionally, these financial instruments will cease to be registered under Section 12 of the Securities Exchange Act of 1934.

Board's Recommendations

The Company's board of directors, guided by an independent committee, has unanimously recommended that shareholders vote in favor of the Merger Agreement at the EGM. The recommendation includes authorization for the merger and the related transactions.

Eligibility and Voting

Eligible shareholders must be on record by 5 p.m. Cayman Islands time on January 16, 2026, to participate in the EGM and any subsequent adjournments. The Company encourages stakeholders to prepare for the meeting and vote accordingly.

Further Information

Comprehensive details regarding the EGM and the Merger Agreement are available in the transaction statement on Schedule 13E-3 and the definitive proxy statement filed with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed at www.sec.gov. For further inquiries about the definitive proxy statement, shareholders can contact the Company's Investor Relations Department at +86 (10) 8920-2086 or via email at [email protected].

About LakeShore Biopharma

LakeShore Biopharma, formerly known as YS Biopharma, focuses on developing vaccines and therapeutic biologics targeting infectious diseases and cancer. The company employs its proprietary PIKA® immunomodulating technology for innovative drug development. With operations across China, Singapore, and the Philippines, LakeShore Biopharma is positioned as a significant player in the biopharmaceutical field.

Forward-Looking Statements

This announcement includes forward-looking statements defined under the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements involve inherent risks and uncertainties, such as uncertainties regarding shareholder voting, potential competing offers, and closing conditions for the transaction. For a thorough understanding, shareholders are advised to review all submitted SEC filings, including the Schedule 13E-3 and related documents.

Related News